drugset / Trial / NCT05222152

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

NCT05222152

Phase 2 Completed 58 enrolled Neurocrine UK Limited
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is a double-blind, double-dummy, two-way cross-over, randomised, Phase II study to be conducted at approximately 6 investigational sites in 2 countries. The study will compare the efficacy, safety and tolerability of twice daily Chronocort, a modified-release hydrocortisone, with once daily Plenadren, a modified-release hydrocortisone, over a treatment period of up to 2 months in participants aged 18 years and over, diagnosed with primary Adrenal Insufficiency (AI).

Timeline

Start
2021-11-23
Primary completion
2023-10-18
Completion
2023-10-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrocortisone Other / unclassified 25 mg Oral